We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Membrane-binding Protein Regulates Cell Motility by Sensing Membrane Tension

By LabMedica International staff writers
Posted on 17 May 2015
A team of Japanese cell biologists has found that the interaction between the degree of plasma membrane tension and a plasma membrane-bending protein regulates cell motility, and that this interaction is disrupted in metastasizing cancer cells.

Investigators at Kobe University (Japan) worked with a cultured tumor cell line in studies that succeeding in identifying the link between the membrane-bending protein FBP17 (formin-binding protein-17) and the degree of tension found at a cell's leading edge formation.

The investigators reported in the May 4, 2015, online edition of the journal Nature Cell Biology that FBP17, an activator of WASP (Wiskott–Aldrich Syndrome protein)/N-WASP-dependent actin nucleation, was a plasma membrane tension sensor involved in leading edge formation. More...
In migrating cells, FBP17 localized to short membrane invaginations at the leading edge, while diminishing from the cell rear in response to plasma membrane tension increase. Conversely, following reduced plasma membrane tension, FBP17 dots randomly distributed throughout the cell, correlating with loss of polarized actin assembly on plasma membrane tension reduction.

In vitro experiments showed that FBP17 membrane-bending activity depended on liposomal membrane tension. Thus, FBP17 was the local activator of actin polymerization that was inhibited by plasma membrane tension in the feedback loop that regulated cell migration. The disruption of cell motility-regulating mechanisms has been cited as a key factor in cancer cell metastasis.

Senior author Dr. Toshiki Itoh, professor of biomedical science at Kobe University, said, "We are promoting research from a less studied perspective to identify new approaches to cancer treatment."

Related Links:

Kobe University



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
All-in-One Molecular System
AIO M160
New
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.